AU2001249928A1 - Full-length gb virus c (hepatitis g virus) rna transcripts are infectious in primary cd4 positive t cells and methods of treating hiv - Google Patents
Full-length gb virus c (hepatitis g virus) rna transcripts are infectious in primary cd4 positive t cells and methods of treating hivInfo
- Publication number
- AU2001249928A1 AU2001249928A1 AU2001249928A AU4992801A AU2001249928A1 AU 2001249928 A1 AU2001249928 A1 AU 2001249928A1 AU 2001249928 A AU2001249928 A AU 2001249928A AU 4992801 A AU4992801 A AU 4992801A AU 2001249928 A1 AU2001249928 A1 AU 2001249928A1
- Authority
- AU
- Australia
- Prior art keywords
- virus
- hepatitis
- infectious
- cells
- primary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19559700P | 2000-04-06 | 2000-04-06 | |
US60/195,597 | 2000-04-06 | ||
US25339000P | 2000-11-27 | 2000-11-27 | |
US60/253,390 | 2000-11-27 | ||
PCT/US2001/011389 WO2001077157A2 (en) | 2000-04-06 | 2001-04-05 | FULL-LENGTH gb virus c (HEPATITIS G VIRUS) RNA TRANSCRIPTS ARE INFECTIOUS IN PRIMARY CD4 POSITIVE T CELLS AND METHODS OF TREATING HIV |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001249928A1 true AU2001249928A1 (en) | 2001-10-23 |
Family
ID=26891123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001249928A Abandoned AU2001249928A1 (en) | 2000-04-06 | 2001-04-05 | Full-length gb virus c (hepatitis g virus) rna transcripts are infectious in primary cd4 positive t cells and methods of treating hiv |
Country Status (3)
Country | Link |
---|---|
US (1) | US6870043B2 (en) |
AU (1) | AU2001249928A1 (en) |
WO (1) | WO2001077157A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003287216A1 (en) * | 2002-10-24 | 2004-05-13 | Sarah George | Gb virus c and methods of treating viral infections |
WO2004108159A2 (en) | 2003-06-05 | 2004-12-16 | The University Of Iowa Research Foundation | Gb virus c (hepatitis g virus) for the treatment of hiv |
US8323891B2 (en) * | 2008-08-01 | 2012-12-04 | Claflin University | miRNA triplex formations for the downregulation of viral replication |
US9611301B2 (en) * | 2012-03-20 | 2017-04-04 | The University Of Iowa Research Foundation | GB virus C (hepatitis G virus) E2 glycoprotein as an immunomodulatory agent |
WO2014152271A1 (en) * | 2013-03-15 | 2014-09-25 | The University Of Iowa Reseach Foundation | Viral proteins as immunomodulaltory agents and vaccine components |
EP3194595A4 (en) | 2014-09-17 | 2018-06-20 | University of Iowa Research Foundation | Viral rna segments as immunomodulatory agents and vaccine components |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5620896A (en) | 1992-03-23 | 1997-04-15 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
US5859230A (en) | 1992-07-30 | 1999-01-12 | Genelabs Technologies, Inc. | Non-A/non-B/non-C/non-D/non-E hepatitis agents and molecular cloning thereof |
US6156495A (en) * | 1994-02-14 | 2000-12-05 | Abbott Laboratories | Hepatitis GB virus recombinant proteins and uses thereof |
US5824507A (en) | 1994-05-20 | 1998-10-20 | Genelabs Technologies, Inc. | Hepatitis G virus and molecular cloning thereof |
US5874563A (en) | 1994-05-20 | 1999-02-23 | Genelabs Technologies, Inc. | Hepatitis G virus and molecular cloning thereof |
EP0885302A1 (en) | 1996-03-05 | 1998-12-23 | The Regents Of The University Of California | Recombinant live feline immunodeficiency virus and proviral dna vaccines |
US5766916A (en) | 1996-04-24 | 1998-06-16 | Genelabs Technologies, Inc. | Hepatitis G virus protease |
KR100564268B1 (en) | 1996-10-23 | 2006-03-27 | 와이어쓰 | Vaccines |
CN1058751C (en) * | 1998-06-15 | 2000-11-22 | 中国人民解放军第二军医大学 | Full length CDNA clone of hepatitis virus G genome and its construction method |
DE60040219D1 (en) * | 1999-06-04 | 2008-10-23 | Us Gov Health & Human Serv | INFECTIOUS CDNA CLONING OF GB VIRUS B AND ITS USES |
-
2001
- 2001-04-05 WO PCT/US2001/011389 patent/WO2001077157A2/en active Application Filing
- 2001-04-05 US US09/828,498 patent/US6870043B2/en not_active Expired - Fee Related
- 2001-04-05 AU AU2001249928A patent/AU2001249928A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001077157A3 (en) | 2002-08-01 |
US6870043B2 (en) | 2005-03-22 |
WO2001077157A2 (en) | 2001-10-18 |
US20030170870A1 (en) | 2003-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1292603B8 (en) | Methods and compositions for treating hepatitis c virus | |
WO2000053729A3 (en) | Viral particles which are released after the infection with the human cytomegalovirus and the use of said particles as a vaccine | |
AU2001236042A1 (en) | Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell | |
HK1097413A1 (en) | Compositions comprising viruses and methods for concentrating virus preparations | |
EP2284268A3 (en) | Conserved HBV and HCV sequences useful for gene silencing | |
AU2003284689A1 (en) | NUCLEIC ACID CONSTRUCT CONTAINING HEPATITIS C VIRUS (HCV) OF GENOCYPE 2a GENOME-ORIGIN NUCLEIC ACID AND CELL HAVING THE NUCLEIC ACID CONSTRUCT TRANSFERRED THEREINTO | |
EP1292329A4 (en) | Manipulation of negative stranded rna viruses by rearrangement of their genes and uses thereof | |
EP1592445A4 (en) | Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell | |
AU2001249928A1 (en) | Full-length gb virus c (hepatitis g virus) rna transcripts are infectious in primary cd4 positive t cells and methods of treating hiv | |
WO2002094844A3 (en) | Antiviral nucleosides | |
AU2001246331A1 (en) | Hepatitis b virus (hbv) antigenic polypeptide-heat shock protein complex and use thereof | |
AU2002225509A1 (en) | Production and of viruses, viral isolates and vaccines | |
WO2003053332A3 (en) | Composition and method for treating viral infection | |
WO2003037265A3 (en) | Method of treating viral infections | |
EP1666598A4 (en) | Nucleic acid and gene originating in novel hcv strain and replicon-replicating cell using the gene | |
AU2001263096A1 (en) | Compositions and methods for production of rna viruses and rna virus-based vector particles | |
AU2001257505A1 (en) | Hepatitis c virus helicase crystals, crystallographic structure and methods | |
AU2003287216A1 (en) | Gb virus c and methods of treating viral infections | |
AU2001277067A1 (en) | Papillomavirus infected epithelial cells and methods of producing infectious papillomavirus in epithelial cells and uses thereof | |
AU2001254670A1 (en) | Detection of hepatitis b virus rna | |
AU4451601A (en) | Genetically engineered clone of hepatitis e virus (hev) genome which is infectious, its production and uses | |
WO2002004595A3 (en) | Production of chimeric human papillomavirus | |
AU2003253255A1 (en) | An immunodeficiency virus (hiv) dna vaccine and to the process of preparation thereof | |
AU2001282560A1 (en) | Methods of infection with hepatitis c virus | |
AU2003257299A1 (en) | Method for inducing complete hepatitis c virus (hcv) replication in vitro |